COMMENT: What’s Really Behind Roche’s Interest In Chugai?
This article was originally published in PharmAsia News
Following initial mass media reports, speculation is rising that Roche may soon exercise an option to acquire the roughly 39% of Japanese firm Chugai that it does not already own. The possible reasons for such a deal are not clear cut however.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.